 Westport, CT, July 02, 2021 GLOBE NEWSWIRE -- BioSig Technologies, Inc. Nasdaq: BSGM BioSig or the Company, a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, 0.001 par value per share, at a price to the public of 4.00 per share. The gross proceeds to BioSig from this offering are expected to be approximately 10 million, or approximately 11.5 million if the underwriter exercises its 30-day option to purchase an additional 15 of the number of shares of common stock offered in the public offering in full, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig. The offering is expected to close on July 7, 2021, subject to the satisfaction of customary closing conditions. 